A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Condition(s):Tuberculosis; Human Immunodeficiency VirusLast Updated:August 25, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Tuberculosis; Human Immunodeficiency VirusLast Updated:August 25, 2023Recruiting
Condition(s):HealthyLast Updated:June 3, 2014Completed
Condition(s):Infections, BacterialLast Updated:April 22, 2015Withdrawn
Condition(s):Long QT Syndrome; HypoglycemiaLast Updated:April 14, 2022Completed
Condition(s):Generalized Aggressive Periodontitis; Aggressive PeriodontitisLast Updated:November 2, 2018Completed
Condition(s):Postoperative Complications; Antibiotic Reaction; Antibiotic Side Effect; Antibiotic Resistant Infection; Antibiotic Resistant Strain; Infection, Bacterial; Infection, LaboratoryLast Updated:June 15, 2022Active, not recruiting
Condition(s):Epithelium, CornealLast Updated:July 17, 2013Completed
Condition(s):Healthy VolunteersLast Updated:October 14, 2019Completed
Condition(s):Infection, Human Immunodeficiency VirusLast Updated:May 21, 2012Completed
Condition(s):Chronic Obstructive Pulmonary Disease; Lung DiseaseLast Updated:February 16, 2011Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.